Clinical Trial

Psilocybin Administration With 5-HT1a Blockade

Study acronym: PsilBlock1
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep and dreaming through the use of sleep EEG and sleep and dream diaries.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-26
Trial Details
NCT Number NCT07565493
Lead Sponsor Johns Hopkins University
Conditions Psychedelic Effects in Healthy Volunteers
Enrollment 18 participants
Start Date 2026-08-12
Primary Completion 2028-06-15 (estimated)
Study Completion 2028-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-14